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ProliferationDomination of cell proliferation over cell death is a driving force for carcinogenesis, whereas reduced cell prolifera-
tion and increased cell death are characteristic of ageing. We employed published data to estimate representative
mean values of cell turnover times for 31 different organs and tissues in adult humans and animals (when data in
humans were lacking) as well as functional mass loss for 5 organs, accounting for actual mass loss and tissue
conversion to fat, in humans over the adult period, age 25 to 70. We found that greater actual and functional
mass loss was signiﬁcantly associated (P= 0.001 and P b 0.0001, respectively) with the log of shorter cell turnover
times. We propose that this is characteristic of stem cell exhaustion and replicative senescence. In addition, we
provide quantitative evidence that, in many organs, involution is evident even in young adults. On the basis of
published mass measurements of major organs, by analysis of covariance, we identiﬁed examples of signiﬁcant
(P ≤ 0.05), accelerated actual or functional mass loss and ageing from early to late adulthood. We hypothesise
and quantitatively demonstrate that functional mass loss accelerates with ageing by incorporating the contribu-
tion of actual mass loss, tissue conversion to fatty or ﬁbrous tissue, and the presence of apoptotic, necrotic and
senescent cells. We propose that mass loss, linked to replicative senescence, is an evolutionary adaptation that
effectively limits cancer in young adults, as mass loss is ﬁrst apparent soon after the end of the growth period,
accelerating in the more elderly as biological conditions deviate away from those prevailing in youth, when the
selective pressure on pleiotropic genes is greatest.
Crown Copyright © 2014 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Progressive atrophy or involution accompanies ageing and is
characterised by common conditions including Alzheimer disease
(Burns et al., 2010), sarcopenia and osteoporosis. During the age-
related involution of organs and tissues (hereinafter “organs” for brevi-
ty), functional or fundamental tissue integrity is reduced, chieﬂy by
one of four means: ﬁrst, mass loss due to lack of replacement of cells
after apoptosis, necrosis, mitotic catastrophe and perhaps autophagic
cell death; second, irreversible cellular senescence; third, inﬂammatory
cell inﬁltration; and fourth, conversion of a functional tissue to another
form, such as fatty or ﬁbrous tissue. Conversion to fat occurs in most
organs, but particularly in the bone marrow, breast, muscle, pancreas
and thymus. Both ﬁbrous material and fatty inﬁltrates are associated
with chronic inﬂammation, a biomarker of ageing (Chung et al., 2009;
Richardson, 2011b; Schafﬂer et al., 2006).rch and Instrumentation Branch,
Chalk River, ON, Canada.
rdr@aecl.ca (R.B. Richardson),
il.com (Y. Le).
r Inc. This is an open access article uMultiple interwoven mechanisms promote age-related involution,
including increased oxidative stress levels, loss of sex hormones, insulin
resistance (e.g., fatty liver disease), lowered production of growth
hormone, and tissue energy metabolism (Almeida et al., 2007; Krems
et al., 2005). In the case of sex steroids (hormones), their loss due to
gonadectomy or ageing is associated with involution of reproductive
organs, osteoporosis and cognitive decline (Lin et al., 2011).
Shorter cell turnover times (i.e., average renewal time of a cell popu-
lation) have been shown to be associated with an elevated tumour inci-
dence in selected tissues in both humans and rodents (Baserga and
Wiebel, 1969). The predominant cell populations in many organs are
epithelial and stromal cells. In general, epithelial cells have a far higher
turnover and cancer incidence than other types of cells, accounting for
80% of all human cancers. For example, for cells in the jejunum, the
average age of all cells has been calculated at ~10.7 years. However, the
cell replacement time varies from ~5 d for epithelial cells to 15.9 years
for stromal cells (Spalding et al., 2005). The rapid-turnover epithelial
cells give rise to adenocarcinoma, the most common cancer of the
small intestine, while from the stromal cells rarer sarcomas originate.
While several qualitative reports have examined the relationship
between cell proliferation and cell death in a speciﬁc tissue, a quantitative
study of multiple organs is lacking. To advance our understanding ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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investigated whether mass loss in a variety of organs was associated
with cell turnover times for these organs. Furthermore, we determined
the age atwhich organmass peaks or plateaus, the age afterwhichmass
loss begins, andwhethermass loss accelerates over adult life. Therefore,
we systematically reviewed published studies of cell turnover time and
organ mass loss, and analysed data from these studies to determine
changes in the rate of mass loss between early and late adulthood. We
then examined our results to discuss whether the relationships found
support current theories of the effects of radiation and of normal ageing.
2. Materials and methods
2.1. Cell turnover time and organ mass loss
Wesearched thepublished literature for reported cell turnover times
for variouswhole organs and tissues, or for their major andmost rapidly
replaced cell component. Data in humans were preferentially selected
where available; in the absence of data in humans, we used data from
rats or, if there were no data from rats, from mice. As organ turnover
times vary with age, those tabulated were of younger, rather than
older, adults. When turnover times were not available, they were esti-
mated as the reciprocal of the fractional turnover rate (fraction per
day) or from half-life (day) data by dividing by the natural logarithm
of 2.
Reported turnover times for different parts of the respiratory tract,
dominated by endothelial cells, are particularly divergent. The bronchi-
oles, alveolar ducts and sacs, rather than the tracheobronchial tree,make
up themajor part (N90%) of the lungmass. No estimatewas foundof the
turnover time for Type I epithelial cells, which constitute N95% of the
alveolus surface. The turnover time of 200 d for the bronchioles of rats
by Blenkinsopp (1967) was selected as the representative value,
although an even slower proliferation was measured by Rawlins and
Hogan (2008) for bronchioles in mice (mean half-life 470 d).
Aswell, we searched for publications reporting the change in “actual”
organ mass in adults from the age of 25 to 70 years, or as close to those
years as possible. For example, organ mass for adults 25 years old were
evaluated in some instances as the mean of two reported values
for 20–24 and 25–29 years old. An allowancewasmade for small (within
5 years) deviations from the 45-year range (e.g., Dekaban and Sadowsky,
1978 reported results for ages 20–30 years to 70–80 years). The upper
age range was limited to 70 years of age principally owing to a paucity
of data beyond this age. For the bone marrow (Bain et al., 2010;
Richardson and Dubeau, 2003), breast, muscle (Marcus et al., 2010), pan-
creas (Saisho et al., 2007) and thymus (Steinmann et al., 1985), we went
someway to estimating functional mass loss by reducing the actual mass
due to tissue conversion to fat. For the breast, the functional mass change
from 25 to 70 years was evaluated as the decrease in non-fat tissue
(collagen/ﬁbrous and glandular) by 31% and 38% from the mammo-
graphic density studies by El-Bastawissi et al. (2000) and Li et al.
(2005), respectively. Using the data of El-Bastawissi et al. (2000), the
mid-range values for the non-fat tissue of four age groups was derived
from four breast density ratings. Using the data of Li et al. (2005), the
difference in the non-fat tissue of two age groups, mean ages 33 and
64 years, was linearly extrapolated to a 45-year range.
Linear correlation analysis was carried out to determine the strength
of the relationship between organ turnover times andmass loss. Organs
were excluded from the analysis if data regarding cell turnover times or
mass changeswith ageingwere lacking, or if the representative cell type
most rapidly replaced constituted ≤10% of the organ volume.
2.2. Mass loss onset and acceleration
The age at onset of mass loss was identiﬁed as occurring after peak
mass, and speciﬁcally as the age or mid-range age that mass loss begins
and continues with age. Organ mass loss onset and acceleration withageing for most organs was analysed employing the published data in
six different examinations, described below. For the remaining organs,
the age at onset of mass loss was estimated on the basis of previously
published studies (Table 1). Lastly, for all organs exhibiting continuous
mass loss (deﬁned as continuous loss except for one time point) with
ageing, the age at onset for each organ was estimated by selecting the
mid-point of an age range and averaging by laterality and sex, where
appropriate. Further, the acceleration of mass loss during early and
late age periods was calculated in the last three examinations. Slopes
from regression analyses of mass change rates between the early and
late age periods were statistically compared by analysis of covariance
(ANCOVA).
First, we examined the constant mass loss rate of four organs during
adulthood by linear regression analysis using autopsy data provided by
He et al. (2009).
Second, age-dependent bone marrow mass was estimated, taking
into account skeletal growth, bone marrow cellularity, and apoptotic
cells (Bain et al., 2010; Richardson and Dubeau, 2003). Apoptotic cell
data was interpolated and extrapolated from 6.5, 7.2 and 19.6% of
human bone marrow cells exhibiting apoptosis at 10, 55 and 90 years
of age, respectively (Ogawa et al., 2000).
Third, the age-dependent analysis of three female sex/reproductive
organs were individually estimated from one published study if the
age range of the data was adequate, or two separate studies if not.
Representative parameter values of mass loss onset were estimated
from data for breast tissue conversion to fat (Boyd et al., 2010), ovary
volume (Cohen et al., 1990), and endometrial thickness (Amir et al.,
2007; Gurbuz et al., 2004).
Fourth, for six organswe used autopsy data by Ogiu et al. (1997), for
age points ti, (yearly until age 19 years, midranges of ﬁve-year periods
for N19 years and a ten-year period, 85–95 years). We calculated the
rate of actual mass change by a three-time-point (ti−1, ti, ti+1)
moving-window, linear regression analysis. The onset age ti of mass
loss was then conservatively identiﬁed as the age when the rate became
consistently negative (one point exception allowed) from that age on-
wards. Linear regression analyses were carried out for an early period
starting at onset age of mass loss (e.g., 22–52 years), followed by a late
period with a generally similar number of age points (e.g., 57–90 years
old). The same analysis was applied to the functional pancreatic mass
values (not tabulated). The adrenals, heart, thymus and thyroid were
excluded from the analysis of data by Ogiu et al. (1997) due to lack of
consistency in mass loss rate in adulthood.
Fifth, the functional mass loss (equivalent to functional volume loss
assuming 1 g·cm−3) of the thymus was estimated from the data of
Steinmann et al. (1985) for mid-range ages by evaluating the functional
thymic volume as comprising the thymic epithelial space and lympho-
cytic perivascular space.
Sixth, changes in the actual body cell mass, and actual and functional
skeletal muscle mass, were based on Kyle et al. (2001), which reported
regression analyses for data divided into two age groups (17–59 years
old and 60–94 years old). Comparison of early and late mass rates was
carried out on data acquired by digitizing the relevant published ﬁgures.
Onset of mass loss was evaluated from the mean mass of decadal age
groups.
3. Results
3.1. Cell turnover time and organ mass loss
Weexamined reports of 31 organs or theirmajor cell types (Table 1).
Cell turnover times for the organs or their cell types had a very wide
range, from 1.4 to 25300 d (Table 1, Fig. 1A and B). The gastrointestinal
tract, thymus and bone marrow were found to have high cellular turn-
over, whereas the heart, brain, bone, and muscle have low turnover
and regenerative capacity. For consistency, we report cellular turnover
times in young adults, where possible, as evidence shows that turnover
Table 1
Mean or mid-range of turnover time of the major proliferative cell component of organs in adult species (humans, rats, or mice); and percentage change in actual or functional mass of
organs from humans approximately 25 to 70 years old.
Organ Functional tissue
change in elderly
Major (and most
rapid) cell types
Species organ
turnover (mean)
days
Turnover
methodsa
Turnover
references
Human mass
change, actual
(mean) and [FM], %
Mass change references.
Country of populationb
Adipose tissuec Adipose H: 4451,
444 (2448)
2H2O,14C-DNA Strawford et al.,
2004; Spalding
et al., 2008
Adrenal Cortex,
neuroendocrine
R: 455 [cortex] 3H-thy. Leblond, 1964 −9, 3 (−3) Tanaka, 1992, J,; Ogiu
et al., 1997, J,
Bonec,d Osteopenia,
osteoporosis
Osteocytes H: 7000 Ref. value ICRP, 1975 −21 Popovic, 2006, VS
Bone marrow,
active
Cellularity loss,
anaemia
Myeloid,
lymphoid
H: 3.2
[red marrow]
Ref. value ICRP, 1975 0 [FM−35] Richardson and Dubeau,
2003, VS; Bain et al.,
2010, VS
Brain Dementia (Glia), neurons H: 16,425
[grey matter]
14C-DNA Spalding et al.,
2005
−6,−3,−6,−9,
−8,−7 (−6)
Dekaban and Sadowsky,
1978, report 6 VS;
Harper and Mina, 1981,
C; Tanaka, 1992, J; Ogiu
et al., 1997, J; Sanchez
et al., 1997, VN;
He et al., 2009, US
Breast Lobular
involution
ET H: 22, 8.8, 13,
143 (47)
3H-thy., 3H-thy.,
3H-thy., 2H2O
Meyer, 1977;
Russo et al.,
1987; Potten
et al., 1988;
Misell et al., 2005
0, 0 [FM−35]e El-Bastawissi et al.,
2000, US; Li et al.,
2005, US
Cervixc Endometrial
involution
(ET), smooth
muscle cells
H: 5.7 3H-thy Richart, 1963
Colorectumc Mucosal and
muscular atrophy
(ET), smooth
muscle cells
H: 3.5,
3.2 (3.4)f
3H-thy., 3H-thy. Cole and
McKalen, 1961;
Lipkin, 1965
Corneac,d Corneal thinning ET H: 7.0 3H-thy. Hanna et al.,
1961
−10 Martola and Baum,
1968, US
Duodenumc Mucosal and
muscular atrophy
(ET), smooth
muscle cells
H: 2.0,
5.5 (3.8)
Colchicine,
3H-thy.
Bertalanffy and
Nagy, 1961;
MacDonald et al.,
1964
Heart Enlarged heart Cardiomyocytes H: 25300, 4290
(14800)
14C-DNA, Ki-67 Bergmann et al.,
2009; Kajstura
et al., 2010
+15, +28,−20,
+18, +20,
+6 (+11)
Bean, 1926, US;
Womack, 1983, US;
Olivetti et al., 1991, IT;
Tanaka, 1992, J; Ogiu
et al., 1997, J; He et al.,
2009, US
Kidney (ET), nephrons,
stroma
R: 270 [cortex] 3H-thy. Leblond, 1964 −7,−9,−7,
−9 (−8)
Bean, 1926, US; Tanaka,
1992, J,; Ogiu et al.,
1997, J; He et al.,
2009, US
Liver Fibrotic & fatty
liver
Hepatocytes R: 453, 201 (327) 3H-thy., 3H-thy. Macdonald,
1961; Zajicek
et al., 1985
−13,−17,−16,
−9 (−14)
Bean, 1926, US; Ogiu
et al., 1997, J; Tanaka,
1992, J,; He et al.,
2009, US
Lung Pulmonary
ﬁbrosis
ET R: 200g 3H-thy. Blenkinsopp,
1967
+2,−6 (−2) Tanaka, 1992, J; Ogiu
et al., 1997, J;
Muscle Sarcopenia Myocyte H: 5510 14C Spalding et al.,
2005
−9,−8 (−9)
[FM−15]
Lee et al., 2000, UC; Kyle
et al., 2001, C
Oesophagusc (ET), smooth
muscle
H: 10 Colchicine Bertalanffy, 1964
Ovary Atresia
(follicle loss)
ET H: 14 Ref. value Follicular phase,
ICRP, 1975
−46 Cohen et al., 1990, US
Pancreas Atrophy, ﬁbrosis
and fat
(ET), acinar cells M: 84, 190,
520 (265)h
3H-thy., 3H-thy.,
3H-thy.
Magami et al.,
1990; Nakayama
et al., 2003;
Cameron, 1970
−3,−8,−4 (−5)
[FM−14]
Tanaka, 1992, J,; Ogiu
et al., 1997, J; Saisho
et al., 2007, US
Parathyroid Chief cells, (ET) R: 1160 Ki-67 Wang et al., 1996 −5 Gilmore and Martin,
1937, UK
Pituitaryc Somatotrophs −2 Tanaka, 1992, J
Prostatec,i Nodular
prostatatic
hyperplasia
ET +86, +54, +47,
+74 (+65)
Swyer, 1944, UK;
Törnblom, 1946, S;
Pradhan and Chandra,
1975, US; Ghartimagar
et al., 2012, IN
Skin
(epidermis)
Epidermal
thinning
ET H: 64j Ref. value Halprin, 1972; j −29,−10,
−15 (−18)
Branchet et al., 1990, F;
Batisse et al., 2002, F;, D;
Gambichler et al.,
2006, G
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Table 1 (continued)
Organ Functional tissue
change in elderly
Major (and most
rapid) cell types
Species organ
turnover (mean)
days
Turnover
methodsa
Turnover
references
Human mass
change, actual
(mean) and [FM], %
Mass change references.
Country of populationb
Small intestinec Mucosal and
muscular atrophy
(ET), smooth
muscle
H: 4.0 3H-thy., 3H-thy Lipkin, 1965;
Shorter et al.,
1964
Spleen Mesothelial cells,
lymphocytes
(ET),
lymphocytes
R: 7.8 32P-MC Andreasen and
Ottesen, 1945
−17,−38,−23,
−31,−31,−30
(−28)
Bean, 1926, US; Boyd,
1933, US; Krumbhaar
and Lippincott, 1939, US;
Tanaka, 1992, J; Ogiu
et al., 1997, J; He et al.,
2009, US
Stomachc Atrophic gastritis (ET), smooth
muscle
H: 1.4 3H-thy Lipkin, 1965
Testis Spermatogonia
and Sertoli cells
Spermatogenesis H: 64 3H-thy Heller and
Clermont, 1963
−4,−17,−9
(−10)
Handelsman and Staraj,
1985, A; Sosnik, 1985, P;
Tanaka, 1992, J;
Thymus Thymic
involution
(ET),
lymphocytes
R: 2.4 32P-MC Andreasen and
Ottesen, 1945
−31, +6,−23,
−13 (−15) [FM
−82]
Krogman, 1941, US;
Steinmann et al., 1985,
G; Tanaka, 1992, J; Ogiu
et al., 1997, J
Thyroid Varies with diet Follicular colloid
nodules
H: 3180
[nodules]
3H-thy Coclet et al., 1989 +12,−3,−11
(−1.0)
Mochizuki et al., 1963,
US; Tanaka, 1992, J,;
Ogiu et al., 1997, J
Urinary
bladderc
ET R: 49 Colchicine Leblond and
Walker, 1956
Uterus Endometrial
involution
ET H: 13 Proliferative and
menstrual phases
−35k Gurbuz et al., 2004, T;
Amir et al., 2007, I
Vaginac ET R: 3.9 Colchicine Bertalanffy, 1964
ET = epithelial tissue; FM = functional mass; H = humans; M = mice; R = rats.
a Atmospheric 14C in DNA (14C-DNA), colchicine-blockedmetaphases (Colchicine), heavywater (2H2O) labelling, review or reference value (Ref. value), tritiated thymidine (3H-thy.) in DNA,
Ki-67 (Ki-67) expression, and 32P mitotic counting (32P-MC).
b A = Australia, C = Caucasian, D = Denmark, F = France, G = Germany, IN = India, IS = Israel, IT = Italy, J = Japan, P = Poland, S = Sweden, T = Turkey, US = United States,
UC = US and Canada, UK = United Kingdom, VN = Venezuelan, VS = various.
c Excluded from analysis due to lack of turnover or mass change data.
d Excluded from analysis as living cells are a small portion (≤10%) of organ.
e Estimate based on Li et al. (2005), used mean ages supplied by N.F. Boyd.
f Average of colon and rectum values.
g Representative turnover for lung mass excluding tracheobronchial tree.
h Excluding outlier value of Tsubouchi et al. (1987), as differs by N10 times standard deviation of other studies.
i Excluded from analysis as no turnover or mass loss data available for males without benign prostatic hyperplasia.
j Halprin's value derived from studies employing various methods, e.g., 14C-glycine, tritiated thymidine, and ﬂuorescent staining.
k Based on endometrial thickness, 25 to 45 years (Amir et al., 2007) and 45 to 70 years (Gurbuz et al., 2004).
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(Bergmann et al., 2009), and in sexual organs, e.g., breast epithelial cells
(Kajstura et al., 2010; Meyer, 1977; Misell et al., 2005; Russo et al., 1987).
“Functional” mass loss was estimated for ﬁve organs in which the
“actual” tissue mass is converted to fat with age. Actual and functional
organmasswas lost fromage 25 to 70 years in all organs studied, except
the heart and prostate. Most measurements were based directly on
autopsy mass, or on thickness in the case of cornea and skin (including
use of optical coherence tomography, Gambichler et al., 2006); for
ovary, ultrasound was used to obtain the volume.
Thirteen organs were excluded from the regression analysis of
turnover and mass loss according to exclusion criteria (identiﬁed in
Table 1); in particular, where data on mass loss for the gastrointestinal
tract are unavailable, where no studies were found of epithelial cell
turnover or organ mass loss in the prostate in the absence of hyperpla-
sia, and where cells with the most rapid turnover constituted ≤10% of
organ volume in cornea and bone.
Table 2 provides the regression analysis results for a semi-log plot of
overall organ turnover times in relation to the percentage change in
actual or functional organ mass.We found that greater actual and func-
tional mass loss was signiﬁcantly associated with the log of shorter cell
turnover times whether the turnover data were limited to organs with
data obtained solely from humans (P= 0.008 for actual and P= 0.002
for functional mass loss) or extended to organs with data from humans
and animals (P = 0.001 for actual and P b 0.0001 for functional mass
loss). When breast and reproductive organs were excluded from the
analysis, we found weaker but signiﬁcant associations for organs withdata solely from humans (P = 0.03), and with data from humans and
animals (P = 0.001).
Our regression model indicates that more than two-thirds of the
human variability of the actual (R2 = 0.72) and functional mass loss
(R2 = 0.70) is explained by the log of the turnover times (Table 2).3.2. Onset of mass loss
Organ mass loss with ageing was analysed employing published
data in six different examinations. The ﬁrst three considered a constant
mass loss rate during adulthood, whereas the latter three examinations
investigated the potential for accelerated mass loss (see Acceleration of
mass loss section below). The onset of organmass loss with ageing was
identiﬁed from the data of all six examinations, three of which, Ogiu
et al. (1997), Steinmann et al. (1985) and Kyle et al. (2001) are shown
in Table 3.
He et al. (2009), using US autopsy data for brain, kidneys, liver,
and spleen, demonstrated highly signiﬁcant negative relationships
(P ≤ 0.01) between organ mass and age of adult males (aged
19–84 years) and females (aged 19–88 years). Investigation of
mass loss onset age (and acceleration) was not possible using the
data of He et al. (2009), as the study provided regression parameters
rather than tabulating mass by age.
Skeletal bone marrow is gradually invaded by fat cells from birth
onwards. Its functional mass, accounting for growth, cellularity (Bain
et al., 2010; Richardson and Dubeau, 2003) and apoptotic cells (Ogawa
84 R.B. Richardson et al. / Experimental Gerontology 55 (2014) 80–91et al., 2000) peaks at about 25 years of age and declines from 40 years
onwards (R2 = 0.97, P = 0.01; Fig. 2B).
An early onset (and continued decline) of actual or functional mass
loss is also evident from analysis of published representative parameters
for the mass of female sex/reproductive organs. Breast lobular involution
and fat content is at a minimum in adolescents, increasing in young
women of 19–30 years (Boyd et al., 2010; Milanese et al., 2006). Ovary
volume peaks at 20–29 years and decreases at 30–39 years of age
(Cohen et al., 1990), and endometrial thickness peaks at 17–25 years
and thins at 26–35 years (Amir et al., 2007).
Ogiu et al. (1997) provided post-natal mass for the whole body and
major non-reproductive organs in Japanese subjects. Mean body height
peaked at 20–24 years of age inmales and at 18 years of age in females,
and then gradually decreased, whereas body weight for this low-obesity
population was at its maximum at 35–39 years of age in males and
50–54 years of age in females. For this study, gradient trend analysis
identiﬁed four of the 10 reported organs as exhibiting inconsistent
mass loss during adulthood (adrenals also undergo involution in a differ-
ent temporal pattern, beginning around birth). The adrenals, heart,
thymus, and thyroid were therefore excluded from further analysis. By
our analysis, the age at onset of continuous actual mass loss in adulthood,
by organ from earliest to latest, was spleen at 22 years (for both sexes);
brain at 27 and 37 years (males and females, respectively); liver at 42
and 47 years (males and females, respectively); kidneys at 47 years
(for both sexes); pancreas at 47 years (for actual and functional mass,
both sexes); and lung at 52 and 47 years (males and females, respective-
ly). The average age of onset of continuous mass loss for the six organs
combined was 42 and 47 years for males and females, respectively.
According to the data of Ogiu et al. (1997), the thymus exhibited
erratic mass loss commencing a year after the peak actual mass at 12
and 10 years for males and females, respectively. This can be compared
with post-natal measurements of the functional thymus (e.g., 24 cm3
at 1/2 year, 22 cm3 at 2.5 years, 17 cm3 at 12 years, 13 cm3 at 22 years,
5 cm3 at 50 years, and 2 cm3 at 88 years) obtained by Steinmann et al.
(1985), who reported that its principal component, the thymic epithelial
space, involuted rapidly from the ages of 1 to 10 years (Table 3).
Of the remaining organs for which mass change values are listed in
Table 1, continuous mass loss was not evident in the parathyroid
(Gilmore and Martin, 1937) or pituitary (Tanaka, 1992). However, after
peaking in the previous period, continuous mass loss was reported for
trabecular bone starting from 31 to 40 years (Popovic, 2006); peripheral,
but not central, cornea thickness from 31 to 40 years (Martola and Baum,
1968); epidermis, but not superﬁcial dermis, from 30 to 40 years
(Branchet et al., 1990); and testis from 30 to 34 years (Tanaka, 1992).
In summary, age for the onset of actual mass loss (average of male
and female) for the thymus is around 12 years old; spleen, 22 years;
uterus, 31 years; brain, 32 years; testis, 32 years; ovary, 35 years;
skin, 35 years; cornea, 36 years; trabecular bone, 36 years; muscle,
43 years; liver, 45 years; kidney, 47 years; pancreas, 47 years; and
lung, 50 years. The onset of functional mass loss can be earlier than
the actual mass, with the thymus around 1 year; breast, 25 years;
bone marrow, 40 years; muscle, 40 years; and pancreas, 47 years.
3.3. Acceleration of mass loss
The potential for accelerated mass loss was investigated in three
examinations by comparing linear regression mass change rates during
early and late age periods and determiningwhether these rates (slopes)
were signiﬁcantly difference (P ≤ 0.05) by ANCOVA (Table 3).
Continuing study of autopsy data by Ogiu et al. (1997), we conducted
linear correlation analysis for the organs with continuous mass loss to
determine whether the mass loss rate changed between an early period
commencing at the onset of mass loss and a late period, each period
consisting of roughly equal number of age points (Table 3). In males,
the kidney, liver, and lung exhibited a rate of mass loss greater in the
late than in the early period, although this rate change was signiﬁcantlydifferent (P= 0.008) only for the liver. In females, the brain, kidney, pan-
creas, and spleen exhibited a rate ofmass loss rate greater in the late than
the early period, and this rate change was signiﬁcantly different for the
brain and spleen (P = 0.05 and 0.03, respectively). Surprisingly, the
rate of mass loss accelerated strongly in the six major organs combined
in males (P = 0.0004) but not in females (P = 0.8).
The functional mass loss rate of the thymus (Steinmann et al., 1985)
signiﬁcantly (P= 0.05), and surprisingly, slowed in adulthood compared
to childhood (Table 3).
Also shown in Table 3 are the age-related changes in appendicular
skeletal muscle mass and body cell mass reported by Kyle et al. (2001)
for healthy European males and females in two groups, aged 18 to b60
and N60 to 94 years old. Actual muscle mass values by Kyle et al.
(2001) were modiﬁed in Table 3 and Fig. 2B by subtracting the age-
dependent (linear) percentage fat inﬁltration, from the data of Marcus
et al. (2010).Whereas the actual musclemass loss accelerates in females
only, the functionalmass loss is greater and accelerates during adulthood
for both sexes: the acceleration is signiﬁcant for males only (P = 0.03).
Analysing the body cell mass data of Kyle et al. (2001), the rate of mass
loss increased 2–4-fold from early to late periods of adulthood. These
data, which are a good measure of functional tissue mass, exhibited a
signiﬁcant acceleration (P = 0.0007 in males; P = 0.05 in females) in
mass loss when comparing periods before and after 60 years of age.
4. Discussion
4.1. Cell turnover, mass loss and implications for cancer and ageing
This work provides experimental evidence that the loss of functional
mass in tissueswith ageingmay be related to themitotic rate or rates of
tissue turnover. This observation probably involves longevity regulator
SIRT1, the so-called “skinny gene”, down-regulation of which is associ-
atedwith cellular senescence of endothelial cells and accelerated ageing
(Bai et al., 2014). It is particularly relevant to our ﬁndings that the
decline of SIRT1 protein with ageing is greatest in mitotically active
tissues (Sasaki et al., 2006). Similarly supportive is that highly prolifer-
ative tissues exhibit greater telomere erosion with ageing, hence a
higher potential for replicative senescence (Ishii et al., 2006). The latter
state is present at considerable levels (N15%) in mitotically active skin
ﬁbroblasts of aged baboons, whereas fewer (b3%) senescent cells are
present in their mitotically inactive muscle (Jeyapalan et al., 2007).
In young adults, tissue maintenance involves the removal of old,
damaged cells and their replacement by stem cells providing progeni-
tors. In adults approaching old age, we have shown lack of homeostasis
andmass loss to bemore prevalent in themost proliferative tissues. Two
means of losing functional mass involve the p53 protein, namely pro-
grammed cell death (without cell replacement) and cellular senescence.
Inactivation of these processes can have severe consequences. On the
one hand, one of us (Richardson, 2013) showed that p53 genemutations
are involved in approximately one-third of the ageing-related rise in the
incidence of all cancers worldwide. On the other hand, mice with
increased p53 activity had a cancer incidence only 1/8th that of normal
mice, yet aged prematurely, with a 23% reduction in median lifespan
(Tyner et al., 2002). By contrast, mice breed by Garcia-Cao et al. (2002)
with extra copies of p53 genes were cancer-resistant but showed no
accelerated ageing. These augmented p53 responses in mutant mice,
with unambiguous beneﬁts concerning p53 and cancer yet ambiguous
effects on p53 and ageing, indicate that other factors also play a
prominent role in ageing.
The breast is a well-documented example of an organ in which a
slower turnover time and greater functional mass loss have been report-
ed to inﬂuence the cancer rate (Milanese et al., 2006; Misell et al., 2005).
The glandular epithelium in the breast is a tissue that atrophies com-
mencing at age 19 to 30 years, with lobules replaced by fat and ﬁbrous
tissue (Boyd et al., 2010; Li et al., 2005). The post-menopausal hormonal
decline contributes to a slower proliferation rate and increased cell death
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Fig. 1.Mass change from age 25 to 70 years correlates with log of organ cell turnover: lin-
ear regression trendlines shown. (A) Functional mass change versus log turnover for
humans only, 10 organs, R2 = 0.70, P = 0.002 and (B) Actual mass change versus log
turnover for humans and animals (rats, mice), 16 organs, R2 = 0.53, P = 0.001.
85R.B. Richardson et al. / Experimental Gerontology 55 (2014) 80–91of ductal epithelial (stem) cells where breast cancer originates, which in
non-obese populations are accompanied by a reduction in the (log–log)
age-dependent breast cancer rate (Misell et al., 2005; Pike et al., 1993).
Nonetheless, our tentative ﬁnding that males have, in general, a greater
acceleration of mass loss in some major organs and body cell mass than
females, yet accompanied by comparatively higher cancer rates, points
to unknown complexities involving senile mass loss.
Similar to human breast epithelial cells, other organs and tissues,
including non-sex-related organs (e.g., pituitary), have proliferative
rates that slow with ageing, attended by a reduced ability to repair
double strand breaks by homologous recombination (Misell et al.,
2005; Nolan et al., 1999). However, there are beneﬁts to a slowing of
mitotic activity, as seen in calorie-restriction experimentswith animals:
lower reactive oxygen species, less cancer, lower reproductive ageing
and reduced general senescence (Lok et al., 1990; Marchal et al., 2013).Table 2
Regression parameters for percentage mass change, both actual and functional, in organs from
Organs Mass change Organs (n)
Human Actuala 8
Human Functional 10
Human, excluding sex-related Functional 6
Human and animal Actuala 16
Human and animal Functional 18
Human and animal, excluding sex-related Functional 14
a Bone marrow and breast excluded owing to lack of mass change data.4.2. Cell turnover, mass loss and possible role of replicative senescence
We found that, in normal ageing, organ mass loss is associated with
high cell turnover. At the Hayﬂick limit, cells go into a senescent state of
persistent cell cycle arrest, or undergo cell death, usually by p53-
dependent apoptosis (Bree et al., 2002; Hayﬂick and Moorhead, 1961).
This increase in apoptotic and senescent cells with ageing represents a
loss of actual and functional tissue. We suggest that this mass loss
may be characteristic of stemcell exhaustion as seen inmuscle andmar-
row (Renault et al., 2002; Richardson, 2011b) and that “replicative
senescence”may play a role in this process. Stemcell pools can diminish
with age. For example, the number of satellite cells in human skeletal
muscle declines from young to old adults (Renault et al., 2002). Further-
more, stem cell exhaustion may be due to cell dysfunction characterised
by decreased self-renewal and quiescence, increased doubling time, de-
graded niches and impaired terminal differentiation (Zhou et al., 2008).
More rapid turnover of tissue stem cells and their progeny leads to
faster rate tissue loss due to telomere erosion and replicative senescence
(Allsopp et al., 1995), particularly if cells are telomerase-negative or if
telomeres are lessmaintained due to the inevitable reduction of telome-
rase activity that occurs with ageing (Mariani et al., 2003). Although
telomerase is generally more active in rodents than humans, even so,
telomere erosion linked to rat development and ageing occurs in the
kidney, pancreas, liver and lung but not brain, an organ with an excep-
tionally long turnover time (Cherif et al., 2003). Most human tissues
andorgans analysed consistently show telomere shorteningwith ageing
(n = 9; Jiang et al., 2007), with the exceptions again having long turn-
over times, e.g., brain, heart, liver and muscle (Renault et al., 2002;
Verma et al., 2012). Employing data from Table 1, a highly statistically
signiﬁcant difference (t test, P = 0.004) was found, with turnover
times (d) of 445± 1032 SD in organs with age-related telomere erosion
and 9266 ± 7657 SD for those reported with more stable telomeres. In
addition, accelerated telomere shortening occurs in various human
diseases associatedwith ageing, e.g., cardiovascular disease,most cancers,
type 2 diabetes and Alzheimer's disease (Jiang et al., 2007; Panossian
et al., 2003; Richardson, 2009).
Yet senescent cells themselves may have a limited lifespan of up to
three years in vitro, followed by cell death by necrosis (Matsumura
et al., 1979). We hypothesized that organs with shorter cell turnover
would exhibit greater replicative senescence, and found that shorter
cell turnover accounted for about two-thirds (Table 2) of subsequent
age-related mass loss in humans due to apoptosis and necrosis, with
the remainingmass loss probably due to other factors such as oxidative
stress, mutation accumulation and stem cell dysfunction.
In fact, oxidative stress is an alternative mechanism for generating
senescent cells (von Zglinicki et al., 2005). Both exogenous and endog-
enous forms of oxidative stress produce “stress-induced (premature)
senescence”, indicated by the secretion of inﬂammatory chemokines
and cytokines (Sabin and Anderson, 2011). For example, high levels of
cell death and inﬂammatory markers are seen in atomic bomb survi-
vors, in whom excess rates of cancer and non-cancer diseases, and
shortened lifespan, are linked to premature ageing (Richardson,
2009). Although in radiation exposure replicative senescence alsoage 25 to 70 years versus the log turnover time in days.
Slope Intercept R (95% CI) R2 P value
12 −46 0.85 (0.36–0.97) 0.72 0.008
11 −45 0.84 (0.44–0.96) 0.70 0.002
9 −38 0.85 (0.13–0.98) 0.72 0.03
9 −33 0.73 (0.37–0.90) 0.53 0.001
14 −51 0.80 (0.52–0.92) 0.63 b0.0001
13 −49 0.66 (0.20–0.88) 0.43 0.01
Table 3
Analysis of published data for organmass, estimating peak and onset age ofmass loss, together with linear regression analyses comparingmass change in an early period and a late period
of ageing.
Organ Male Female
Peak (P) and
onset (O) age (y)
Periods
(y)a
Time
points
Slope
(g·y−1)
R2 P value Mass loss
acceleration
(✓ or ✗)b,
ANCOVA
P value
Peak (P) and
onset (O)
age (y)
Periods
(y)a
Time
points
Slope
(g·y−1)
R2 P value Mass loss
acceleration
(✓ or ✗)b,
ANCOVA
P value
Actual mass: Ogiu et al. (1997)
Brain P 12 22–52 7 −4.0 0.89 0.001 ✗ P 12 32–57 6 −2.8 0.87 0.007 ✓
O 27 57–90 7 −3.7 0.88 0.002 0.8 O 37 62–90 6 −4.9 0.92 0.002 0.05
Kidneys (L&R) P 42 42–62 5 −1.2 0.94 0.007 ✓ P 42 42–62 5 −1.2 0.63 0.1 ✓
O 47 67–90 5 −2.8 0.87 0.02 0.06 O 47 67–90 5 −2.1 0.94 0.007 0.2
Liver P 37 37–57 5 −5.8, 0.90 0.01 ✓ P 42 42–62 5 −7.4 0.79 0.04 ✗
O 42 62–90 6 −14 0.95 0.0009 0.008 O 47 67–90 5 −6.2 0.86 0.02 0.7
Lungs (L&R) P 16 47–62 4 −3.5 0.66 0.2 ✓ P 16 42–57 4 −2.9 0.68 0.2 ✗
O 52 67–90 5 −5.1 0.51 0.2 0.7 O 47 62–90 6 −0.9 0.31 0.3 0.2
Pancreas P 42 42–62 5 −0.55 0.81 0.04 ✗ P 18 42–62 5 −0.01 0.001 0.95 ✓
O 47 67–90 5 −0.52 0.71 0.07 0.9 O 47 67–90 5 −0.60 0.79 0.04 0.08
Spleen P 19 19–52 8 −1.0 0.62 0.02 ✗ P 14 19–52 8 −0.5 0.86 0.0009 ✓
O 22 57–90 7 −0.6 0.91 0.0009 0.3 O 22 57–90 7 −1.0 0.89 0.001 0.03
Six organs P 37 37–57 5 −11 0.87 0.02 ✓ P 42 42–62 5 −13 0.83 0.03 ✓
O 42 62–90 6 −28 0.99 b0.0001 0.0004 O 47 67–90 5 −14 0.95 0.005 0.8.
Functional mass, (both sexes mixed): Steinmann et al. (1985)
Thymus— fat P 0.5 0.5–12 4 −0.5 0.99 0.0007 ✗
O 2.5 17–88 9 −0.2 0.95 0.0001 0.05
Actual and functional mass: Kyle et al. (2001)
Musclec P 35 17–58 158 +15 0.0003 0.50 ✗ P 25 18–58 75 −6 0.001 0.78 ✓
O 50 65–94 95 −98 0.076 0.007 0.02 O 35 62–92 105 −43 0.019 0.16 0.6
Muscle— fatd P 35 17–58 158 −36 0.020 0.08 ✓ P 25 18–58, 75 −38 0.004 0.06 ✓
O 45 65–94 95 −119 0.14 0.0002 0.03 O 35 62–92 105 −54 0.012 0.04 0.6
Body cell massc P 35 17–58 158 −48, 0.019 0.09 ✓ P 18 18–58 75 −76, 0.098 0.006 ✓
O 45 65–94 95 −221 0.24 b0.0001 0.0007 O 25 62–92 105 −164 0.18 b0.0001 0.05
a Mid-range ages.
b Tick indicates greater mass loss rate during late period. Bolded P values indicate statistically signiﬁcant differences between early and late periods.
c Linear regression analysis by Kyle et al. (2001); we evaluated ANCOVA of digitised graphical data.
d Linear regression analysis of digitised graphical data (Kyle et al., 2001), minus fat inﬁltration (Marcus et al., 2010).
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in Chernobyl clean-up workers by Ilyenko et al., 2011), stress-induced
senescence is likely the dominant mechanism.
4.3. Onset and acceleration of mass loss
Our analysis of previously published data indicates that mass loss in
major organs generally begins between 21 and 35 years of age for
reproductive organs and between 22 and 50 years for non-reproductive
organs, although involution of the thymus begins even earlier. Likewise,
many physiological functions show a decline from 30 years of age
(Strehler and Mildvan, 1960). Similarly some aspects of age-related cog-
nitive decline begin in healthy educated adults when they are in their
20s and 30s (Salthouse, 2009). Therefore, our evaluation of organ mass
loss, especially in terms of functional tissue reduction, is in parallel with,
and likely contributes to, the decline in physiological and cognitive
function.
Furthermore, these studies also provide substantial, but not universal,
evidence for the acceleration of actual and functional mass loss in organs
(Table 3). Contrary to this trend, the heart may gain mass later in life
due to as a compensatory response to hypertension, and benign
tumourigenesis of the prostate affects most men after 50 years
(Ghartimagar et al., 2012).
The biological mechanism for the accelerated ageing phenomenon
may involve inﬂammation stimulating the hypothalamus to produce
increased cortisol (Dettenborn et al., 2012), causing glucocorticoid-
induced skeletal and soft tissue atrophy as well as vulnerability to
metabolic syndrome (Youm et al., 2013). Sex hormones could also play
an important role in regulating both cell turnover and loss of tissue
mass through apoptosis (Medh and Thompson, 2000). This accelerationtrend is moderately to strongly signiﬁcant for body cell mass (Kyle et al.,
2001), a good measure of functional tissue mass. We did account for
tissue conversion to fat in ﬁve organs in Table 1 but not for reduction
in functional tissue due to the presence of apoptotic, necrotic or senes-
cent cells (Jeyapalan et al., 2007; Ogawa et al., 2000). As the few studies
dedicated to these ageing changes indicate that these functional tissue
losses may be considerable, this suggests that even measures of body
cell mass underestimate the true accelerating loss of functional tissue
with ageing. Indeed, accelerated functional mass loss could provide an
increased elimination of precancerous cells in the very elderly, perhaps
providing an explanation, among others, for the decrease in cancer
rates observed after age 75 (Magdon-Maksymowicz and Maksymowicz,
2009).
Could this acceleration in ageing be linked to the non-linear increase
innuclear andmitochondrialmutation frequency, and associated apopto-
sis, replicative senescence, carcinogenesis and heritable defects (Pollack
et al., 2002; Richardson, 2009; von Zglinicki et al., 2005)? A non-linear,
age-related rise in nuclear mutations is seen in both somatic and germ
cells accompanied by an exponential increase in the incidence of cancer,
in somatic cells, and sporadic achondroplasia, in germ cells (Richardson,
2013; Tiemann-Boege et al., 2002; Vorobtsova et al., 2001). There is the-
oretical support for the view that children of older parents carry a larger
“mutational burden”, hence inﬂuencing the biological ageing andmortal-
ity rates of their progeny (Magdon-Maksymowicz and Maksymowicz,
2009). However, the experimental evidence is ambiguous regarding
whether progeny of older parents are characterised by premature ageing.
On the one hand, children of older parents have longer telomeres than
progeny of younger parents, a process that may extend late-life function,
as the average age at reproduction is delayed (Austad, 1993; Eisenberg
et al., 2012). On the other hand, persons born of mothers younger than
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Fig. 2. Age-dependent change in muscle and marrowmass. (A) Actual appendicular skel-
etal muscle mass, with and without functional tissue conversion to fat; acceleration of
mass loss is signiﬁcant (P = 0.03, Table 3) for males only (Kyle et al., 2001; Marcus
et al., 2010). (B) Bone marrow mass changes with age, accounting for growth, cellularity
and apoptotic cells (Bain et al., 2010; Ogawa et al., 2000; Richardson and Dubeau, 2003).
87R.B. Richardson et al. / Experimental Gerontology 55 (2014) 80–9125 years are about two timesmore likely to survive to age 100 than their
siblings born to the same mothers at older ages (Gavrilov and Gavrilova,
2012;Gavrilova andGavrilov, 2007). Aswell, a variety of abnormalities in
progeny are associated with greater age of the mother (trisomies) or
father (autism, schizophrenia, sporadic achondroplasia). Regardless of
the origin of ageing, these examples provide evidence that accelerated
ageing, by increasing the likelihood of death, limits the risk that older
parents will reproduce and create amutational burden in their offspring.4.4. Implications of results on theories of ageing
Reproductive value and contributions to ﬁtness decline monotoni-
cally during the reproductive period as fecundity falls and mortality
rises (Hamilton, 1966). At the same time, ageing is accompanied by an
increased likelihood, and the participation, of deleterious mutations.
This has generally been viewed in terms of gene functional trade-offs
and the evolution of pleiotropy (Guillaume and Otto, 2012): genome
evolution being most inﬂuenced when selective pressure is greatest,
before sexual maturity, and decreasing thereafter.
Medawar (1952) argued that ageing occurs and mutations accumu-
late because of its neutral effect on the selection of late-stage deleterious
mutations, since mortality in the wild is mainly accidental and is sufﬁ-
ciently high to prevent organisms reaching old age. On this basis,
Williams (1957) proposed the theory of antagonistic pleiotropy: genes
such as TP53 or TGF-β, and biological processes that enhance reproduc-
tive success early in life, lead to an evolutionary trade-off, with later
ﬁtness decline and death.
In this view, replicative senescence would be one such biological pro-
cess. In terms of cancer, replicative senescence is a double-edgedmecha-
nism: it can both hinder and help oncogenesis. It has been postulated tosuppress cancer when cells become apoptotic or senescent upon their
telomeres reaching a critical length, as long as the proliferation/apoptotic
genes are functional (Campisi et al., 2001; Wright and Shay, 1992). A
case could be made for replicative senescence protecting those with
Alzheimer's disease against cancer. Features of this form of dementia
include telomere/telomerase dysfunction, shortened telomeres, reduced
lean body mass, and brain atrophy. The risk of cancer for patients with
this disease is halved compared with the risk in other people (Burns
et al., 2010; Musicco et al., 2013; Panossian et al., 2003).
Often, replicative senescence is a prerequisite for cancer cells, which
they overcome. It is telling that most cancer cell lines exhibit very short
telomeres but escape replicative senescence through mechanisms such
as telomerase activation or telomeric recombination (Brault and
Autexier, 2011; Jiang et al., 2007). Extensive stem cell proliferation can
foster a telomere erosion crisis, leading to oncogenic development, espe-
cially if accompanied by dysfunctional cell apoptosis or proliferation
genes. A case in point: the unusually short telomeres observed in the
bonemarrow cells ofmyelodysplasia syndrome patients become shorter
still upon the development of acute myeloid leukaemia with associated
FLT3, RB1 or TP53mutations (Sieglova et al., 2004). In this cancer, cells
also exhibit exceptionally high levels ofmethylation ageing. Atmoderate
or high doses, radiation is a telomere-eroding and ageing agent, which in
A-bomb survivors has lead to high relative risks of myelodysplasia
syndrome and acute myeloid leukaemia (Horvath, 2013; Ilyenko et al.,
2011; Richardson, 2009).
We have shown that major organs exhibit a loss of actual and func-
tional mass, attended by physiological or cognitive decline, surprisingly
even in young adults, when reproductive ability and hence natural
selective pressure is close to maximum. This early decline in ﬁtness is
contrary to Medawar's (1952) postulate that ageing occurs after the
reproductive period when selective pressure is lacking. This claim is
therefore refuted by our study, and also by a study showing the onset
of senescence in dogs at 2.2 ± 0.8 years old, when large dogs are not
fully grown (Kraus et al., 2013). The ﬁrst report for an early onset of age-
ing for animals living in thewild is forwolves, which found that the onset
of ageing handicaps their ﬁtness to escape predators (MacNulty et al.,
2009), and presumably their reproductive success. The study found that
the age of peak ability to attack, select and kill elk was at 1 to 3 years,
around the time of ﬁrst reproduction at 2 to 4 years old. One-ﬁfth of
wolveswere still alive at 10 years, subjecting ageing to selective pressure.
Similar conditions apply to premodern humans, including hunter-
gathers, whose modal lifespan (or peak mortality) was estimated at
about 72 years old, with a quarter of all adult deaths at or above mode
(Gurven and Kaplan, 2007). Accordingly, evidence in young adult, wild
animals and premodern humans compellingly suggest that ageing,
and genes and mechanisms identiﬁed as pleiotropic and complicit in
ageing (e.g., TP53, TGF-β and replicative senescence) are subject to
strong evolutionary pressures.
Weismann (1889) suggested the controversial idea that ageingmay
have an evolutionary beneﬁt: advancing death, thereby reducing the
period of reproductive decline and post-reproductive senescence,
hence making the best use of limited resources. In general, a species'
reproductive ability declines with adult age, with death commonly
following shortly after reproductive senescence (Zhao et al., 2008).
There are few exceptions to a short post-reproductive period, such as
when the usually hermaphroditic Caenorhabditis elegans mates with
rarer males (Mendenhall et al., 2011). Whales and humans constitute
other exceptions, as long-lived, post-reproductive females (i.e., mothers
and grandmothers) provide valuable aid to their progeny (Johnstone
and Cant, 2010). Notwithstanding these exceptions, ageing may be
beneﬁcial in reducing the post-reproductive period and providing
nutrients and resources for descendants either indirectly or directly
and altruistically, as in yeast (Mendenhall et al., 2011).
Ageing in animals involves multifaceted mechanisms, including
replicative senescence and epigenetic inheritance, which are generally
considered to be genetically programmed. In most somatic tissues of
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ﬁnishes and sexual maturity is achieved, and continues into old age
until a critical length is reached, when cell replication stops (Jiang
et al., 2007). The general prevalence of the Hayﬂick limit in human
somatic cells, including stem cells, means this aspect of human ageing
is likely an evolutionary adaptation, as antidotes against this shortening,
such as telomerase, are not employed at sustaining levels in somatic
tissues. However, telomere-maintenance mechanisms are fully opera-
tional in human germ cells, most neoplasms (clonal cells) and biologi-
cally immortal species such as Hydra vulgaris that reproduce asexually
when food is plentiful (Boehm et al., 2012; Bridge et al., 2010). The
immortality (and lack of reported mass loss) of Hydra is assigned to
FoxO stem cell maintenance gene variants, which are also found in
human stem cells, albeit at levels insufﬁcient to maintain stem cells.
Interestingly, a genetic variant in the FOXO3a gene region is more
common in German centenarians compared with younger controls
(Flachsbart et al., 2009).
The fact that organ involution is ﬁrst evident in young adults can be
also interpreted to indicate that trade-offs and pleiotropic gene activities
begin to be expressed well before actual mortality. Thymic atrophy, a
form of immunosenescence, begins even earlier in human development:
loss of thymic epithelial space commences at 1 year old in humans
and proceeds at a faster rate before sexual maturity rather than after
(Steinmann et al., 1985). This thymic involution is driven by the pre-
pubertal release of glucorticords, or infective or psychological stress.
This demonstrates complex trade-offs, with an innate immune
response predominating over an adaptive one, whereas impaired
thymus function can, later in life, result in antagonistic pleiotropic
features such as height-deﬁcit, delayed puberty and increased
vulnerability to acute lymphoblastic leukaemia (Kinouchi et al.,
2012; Richardson, 2011a).
Another trade-off, inwhich human lifespan is extended at the cost of
reproductive success, was reported by Westendorp and Kirkwood
(1998) using historical data from the British aristocracy. Conversely,
according to the disposal soma theory, ﬁnite food energy may be
preferentially used for reproduction, compromising repair during
ageing (Kirkwood, 1977). Indeed, the involution we documented
in non-reproductive tissues could be redistributing energy away
from mitotically active tissues to reproductive organs; however, this is
doubtful, as we found a parallel mass loss in reproductive tissues.
The prevailing view is that antagonistic pleiotropy is the dominant
inﬂuence on the genetic architecture of human ageing. According to
this view, beneﬁcial selective pressure on pleiotropic genes arises
from early-stage survival and reproduction trade-offs, with ageing
resulting from selective neutrality of late-stage deleterious mutations
(Guillaume and Otto, 2012). Nevertheless, our research shows that
mass loss in human bone and some soft tissue organs is ﬁrst apparent
soon aftermaturity, during the highly fertile period of young adulthood,
contrary to Medawar's (1952) assertion that ageing is not subject to
evolutionary pressures.We therefore surmise that themass loss process-
es involved are in place and operational even before maturity, yet are
masked or effectively countered by growth. If this mass loss is linked to
replicative senescence that suppresses cancer during a period of strong
selective pressure, then it has proven a highly effective evolutionary
adaptation, as evinced by the very low cancer incidence of late childhood
and early adulthood.
We suggest, based on our ﬁndings, that the mass loss processes
become observable post-maturity, when growth stops. As adulthood ad-
vances, this mass loss accelerates due to further temporal changes
resulting fromhormones and froman increase inmutation accumulation,
chronic inﬂammation and chronic diseases. These temporal changes
cause biological conditions to deviate from those existing before and
soon after maturity, when the selective pressure is greatest on gene func-
tion, including pleiotropy. In light of this, epigenetic inheritance plays an
important role in the ageing process by bringing about temporal changes
in gene activity, such as those due tomethylation ageing (Horvath, 2013).4.5. Limitations of turnover/mass loss data
Our analysis has limitations and uncertainty arising from the use of
published data fromdifferent species and human populations. Of neces-
sity, we relied on data from different international sources utilizing
variousmethods of analysis and interpretation. Eachmethod has its ad-
vantages and limitations. For example, bromodeoxyuridine (BrdU) and
atmospheric 14C in DNAwere both employed by Bhardwaj et al. (2006)
to estimate neocortical neuron turnover. The former method was pref-
erable due to its high sensitivity to detect low-grade continuous cell
generation, while BrdU-labelling labels newborn cells at a given point
of time, with the disadvantage of inaccurate results. In order to aid the
correlation analysis, a single representativemean value of both turnover
and mass change was allocated for each organ. No uncertainty for this
value was assigned, as it was generally estimated from multiple studies
withdata of different andoftenunknownerrors. In addition,we acknowl-
edge a confounding factor in our calculations based ondata fromdifferent
species, as organs from larger animals have lower metabolic and cell
proliferation rates than the same organs from smaller animals (Porter
and Brand, 1993).
There is a lack of continuous age-dependentmass loss data for repro-
ductive organs and the gastrointestinal tract. Comprehensive measure-
ments of alimentary tract wall mass or thickness are particularly scarce
(Haber and Stern, 2000) and complicated by inﬂammatory bowel disease
producing thickening or thinning.
In addition to actual loss of tissuemass in organs, for ﬁve of themwe
also accounted for conversion of functional tissue to fat but did not
account for either the percentage of tissue converted to ﬁbrous material
(e.g., as occurs in thyroid), or for the percentage of cells subject to apopto-
sis (e.g., bonemarrow),moremacrophages, autophagic cell death, necro-
sis, mitotic cell death or senescence (e.g., skin). These omissions were
primarily due to the lack of availability of published age-dependent
data for humans, yet these biological mechanisms make important
contributions to functional tissue mass loss.
5. Conclusion
Our review supports a strongly signiﬁcant association between cell
proliferation and functionalmass loss, the latter being an important indi-
cator of ﬁtness and ageing. We found that two-thirds of the human var-
iability of mass loss can be assigned to the log of tissue turnover times.
We suggest that this is likely characteristic of replicative senescence of
stem cells, which, as the immortalHydra demonstrates, is not a biological
imperative but an evolutionary adaptation, likely suppressing cancer in
humans. The onset of functional mass loss ﬁrst becomes apparent soon
after growth terminates, during the early part of the reproductive period,
when selective pressure is still considerable. We make the case that,
although the deceleration of cell turnover helps mitigate the erosion of
maintenance-deﬁcient telomeres, there is an acceleration of functional
mass loss in old age as biological conditions change from those existing
in early development, when the selective pressure on genetic trade-offs
is most inﬂuential.
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